Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 88 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Islet Transplantation Clear all
Completed Phase 3 Interventional Results available

Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation

NCT01817959
View directory record Official record
Conditions
Islet Transplantation in Diabetes Mellitus Type 1
Interventions
Reparixin, Placebo
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Jun 26, 2026, 2:31 AM EDT
Completed Phase 3 Interventional

Efficacy of Islet After Kidney Transplantation

NCT00468117
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 68 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
9
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Jun 26, 2026, 2:31 AM EDT
Completed Phase 2 Interventional

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

NCT00434850
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin, Daclizumab or basiliximab, Sirolimus, Tacrolimus, Etanercept
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Jun 26, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients

NCT01897688
View directory record Official record
Conditions
Type 1 Diabetes, Severe Hypoglycemic Unawareness
Interventions
Islet Cell Transplant
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jun 26, 2026, 2:31 AM EDT
Recruiting Not applicable Interventional

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

NCT01999361
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Myfortic
Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jun 26, 2026, 2:31 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients

NCT00260234
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Cultured Islet Cells (human); Encapsulated
Biological
Lead sponsor
Novocell
Industry
Eligibility
20 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Jun 26, 2026, 2:31 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation

NCT03513939
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sernova Cell Pouch
Combination Product
Lead sponsor
Sernova Biotherapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 26, 2026, 2:31 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

NCT01206101
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Jun 26, 2026, 2:31 AM EDT
No Longer Available No phase listed Expanded access

Islet Transplant for Type 1 or Surgical Diabetes

NCT01606475
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia, Labile Diabetes, End-stage Renal Disease
Interventions
Allogeneic islets of Langerhans
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jun 26, 2026, 2:31 AM EDT
Completed Phase 1 Interventional

Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes

NCT00708604
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Islet Transplantation, Islet cell transplantation
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 26, 2026, 2:31 AM EDT
Not listed No phase listed Observational

Patterns and Natural History of Insulin Secretion in Islet Cell Transplant Recipients and Controls

NCT00018122
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 26, 2026, 2:31 AM EDT
Completed Phase 1Phase 2 Interventional

Carbon Monoxide-Saturated Medium for Islet Isolation

NCT02567240
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Carbon monoxide-bubbled mediums
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 69 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Jun 26, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation

NCT00315627
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation
Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Jun 26, 2026, 2:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intra-Portal Alone Versus Intra- and Extra-Portal Transplantation of Pancreatic Islets After Total Pancreatectomy for Chronic Pancreatitis

NCT03779139
View directory record Official record
Conditions
Chronic Pancreatitis, Diabetes Mellitus, Islet Cell Transplantation
Interventions
Intrahepatic islets and islets in the omental pouch, Intrahepatic islets alone, Normal Volunteers
Procedure · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 68 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Jun 26, 2026, 2:31 AM EDT
No Longer Available No phase listed Expanded access

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

NCT01049633
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Clotrimazole, Valganciclovir, Heparin, Enoxaparin, Pentoxifylline, Aspirin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Jun 26, 2026, 2:31 AM EDT
Not listed Phase 1Phase 2 Interventional

Islet Transplant in Patients With Type I Diabetes

NCT03698396
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic Islet Cell Transplantation
Biological
Lead sponsor
Kenneth Brayman, MD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Jun 26, 2026, 2:31 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

NCT06575426
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Islet Cell Transplantation, Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D), Severe Hypoglycemia, Xenotransplantation, Hypoglycemic Episode, Islet Transplantation in Diabetes Mellitus Type 1, Glucose Metabolism Disorders (Including Diabetes Mellitus), Immune System Diseases, Autoimmune Diseases, Metabolic Disease
Interventions
OPF-310
Combination Product
Lead sponsor
Otsuka Pharmaceutical Factory, Inc.
Industry
Eligibility
35 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jun 26, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pancreatic Islet Transplantation Into the Gastric Submucosa

NCT01571817
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Isolated Human Pancreatic Islets
Biological
Lead sponsor
Andrew Posselt
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jun 26, 2026, 2:31 AM EDT
Not listed No phase listed Observational

Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant

NCT03415139
View directory record Official record
Conditions
Diabetes Mellitus, Cancer
Interventions
Oral Glucose Tolerance Test (OGTT), 2 OGTTs with and without GLP-1 analogue, Hyperglycemic clamp procedure
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Jun 26, 2026, 2:31 AM EDT
Not listed Phase 1 Interventional

Treatment of Type I Diabetes by Islet Transplantation Into the Gastric Submucosa Study Protocol

NCT02402439
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet cells, Islet transplantation into the gastrointestinal submucosa
Drug · Procedure
Lead sponsor
Andrew Posselt
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jun 26, 2026, 2:31 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors

NCT05453851
View directory record Official record
Conditions
Benign Pancreatic Neoplasm, Chronic Pancreatitis, Recurrent Acute Pancreatitis
Interventions
Pancreatectomy, Quality-of-Life Assessment, Treatment Planning
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jun 26, 2026, 2:31 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

NCT06305286
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jun 26, 2026, 2:31 AM EDT
Completed Phase 1Phase 2 Interventional

Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation

NCT00286624
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Allogeneic Islets of Langerhans, Everolimus, anti-thymocyte globulin, Cyclosporine
Biological · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2008 · Synced Jun 26, 2026, 2:31 AM EDT
Active, not recruiting Phase 2 Interventional

Islet Cell Transplant for Type 1 Diabetes

NCT01909245
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogenic Human Islet Cells, Immunosuppressive Agents, Gastrin 17
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 68 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 26, 2026, 2:31 AM EDT